Akorn Inc Raises FY 2012 Guidance

Akorn Inc announced that its 2012 outlook has been updated to include the impact of vancomycin hydrochloride capsules, but excludes any new approvals after August 7, 2012. For fiscal 2012, the Company expects total revenues of $248-258 million, adjusted net income of $55-57 million, adjusted net income per diluted share of $0.50-0.52 and adjusted EBITDA of $97-100 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $251 million, net income of $57 million and EBITDA of $95 million for fiscal 2012.